Invus — Full Portfolio

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)RSRobert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)SOSteven O'Day(Chief Medical Officer)in

Co-investorsADAdvent Life SciencesGRGrazia Equity GmbHHEHEALTHCARE ROYALTY PARTNERSOBOberland CapitalCOCommodore CapitalLILigand Pharmaceuticals+1 more

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)MGMark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)

Co-investorsPAPappas CapitalABAberdare VenturesECEcoR1 CapitalPOPolaris Partners

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARARCH Venture PartnersBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)PIPivotal Life Sciences+3 more

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechHealthtechBerkeley Heights, US

SASrinivas Akkaraju(Director & Co-founder)MDMike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)

Co-investorsSASamsara BioCapitalRTRTW Investments L.P.

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

PLPaul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)MHMaykin Ho(Director)AHAlaa Halawa(Director)

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPF-F-Prime CapitalK2K2 HealthVenturesMEMercury FundPRPremier Partners+10 more

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO and Board Member)inMCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)inEGEric Green(Executive Officer)in

BoardJIJames I. Healy(Director)

Co-investorsARARCH Venture PartnersFOForesite CapitalHAHAWKTAILPUPureTech HealthSOSofinnova VenturesCPCPP Investments+3 more

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

RWReid Waldman(Chief Executive Officer and Board Member)inTDTim Durso(Chief Technical Officer)inDCDominic Carrano(Chief Financial Officer and Treasurer)inMNMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLOLongitude CapitalCOConnecticut InnovationsLILifeSci Venture PartnersOUOUP (Osage University Partners)SRSR One Capital ManagementABabrdn plc

Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.

Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB

Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)

Co-investorsALAlpha EdisonBRBritish Business BankCHChevron Technology VenturesOXOxford Science EnterprisesBABackstage AB

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

KWKoenraad Wiedhaup(Founder & Chief Executive Officer)inRBRonald Brus(Founder & Chief Growth Officer)inJGJaap Goudsmit(Founding Scientist and Senior Advisor)inDVDinko Valerio(Founder and Chair of the Supervisory Board)inJAJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsCLClavystBioF-F-Prime CapitalGVGV (Google Ventures)BLBluebird VenturesCACasdin CapitalEUEuropean Innovation Council Fund+6 more

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

IDIvana Djuretic(Founder)inAYAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)

Co-investorsEMEmles Venture PartnersGOGoAhead VenturesMIMission Bay CapitalMIMission BiocapitalRARA CapitalY Y Combinator+4 more

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

VPVijaya Pattabiraman(Co-founder & Chief Technology Officer)inJBJeffrey Bode(Scientific co-founder; Professor at ETH Zürich)inFWFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)MRMichael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsRARA CapitalJOJohnson & Johnson Innovation – JJDCVEVersant VenturesVEVenrockALAlexandriaBLBlackRock+2 more

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

MEMichael E. Mendelsohn(Founder and Chief Strategy Officer)inMMMichael Mendelsohn, M.D.(Founder)in

Co-investorsBABain CapitalASAscenta CapitalDEDelos CapitalDIDigitalis VenturesNENew Enterprise Associates (NEA)BABain Capital Life Sciences+4 more

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

MKMark Keating, MD(Co-founder)KNKotaro Nakanishi, PhD(Co-founder)YTYukihide Tomari, PhD(Co-founder)PZPhillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)

Co-investorsANAN Venture PartnersARARCH Venture PartnersSOSofinnova VenturesCACasdin CapitalFIFidelity InvestmentsNYNYBC Ventures+2 more

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFUFund+KUKurma PartnersSESeroba Life SciencesV-V-Bio VenturesBPBpifranceNONovo Holdings+1 more

Datawords operates a network of production studios across local markets to create and deliver localized content at scale for global brands.

AI & Machine LearningEnterprise SoftwareMarketing TechMedia & EntertainmentSector Agnostic

Co-investorsKEKeensight Capital

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGMGeorge M. Church(Director)

Co-investorsALAlta PartnersARARCH Venture PartnersCACatalio Capital Management, LPKHKhosla VenturesLILifeSci Venture PartnersOUOUP (Osage University Partners)+12 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

KKKazuki Kamiya(CEO)SISatoru Ichihara(COO)SHShinya Hayashi(CSO)HIHidefumi Iwaki(CFO)TSTomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANANOBAKACACARTA VENTURES, Inc.SPSpiral VenturesAGAgent CapitalCACasdin CapitalNENextech Invest+2 more

Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

DPDaniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsENEntrepreneur FirstAGAgent CapitalBABase10 PartnersCACasdin CapitalINInovia CapitalNENextech Invest+3 more

Flexiv builds adaptive robots featuring force control, including the Rizon seven-axis robotic arm and Hesper robot controller.

Advanced ManufacturingAI & Machine LearningDeep TechEnergyHardwareRoboticsSilicon Valley, US

SWShiquan Wang(Co-Founder and Chief Executive Officer)inXYXiyang Yeh(Co-Founder and Chief Technology Officer)in

Co-investorsZHZhenFundGAGaorong CapitalGSGSR VenturesPLPlug and Play VenturesYFYF Capital

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)MAMark Angelino(Executive Officer)

BoardJRJason Rhodes(Director)inCSCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsATAtlas VentureFOForesite CapitalCACasdin CapitalDEDeerfield Management CompanyF-F-Prime CapitalFIFidelity Investments

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)DMDavid M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)NENextech InvestVIVida VenturesBLBlackRockCOCommodore Capital+2 more

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DPDAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALALAN L. CRANE(Director)

Co-investorsALAlpha Wave GlobalARARCH Venture PartnersFLFlagship PioneeringLALAVLGLG Technology VenturesLILilly Asia Ventures+3 more

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAIAisling CapitalARARCH Venture PartnersPRProspect Venture PartnersSCSchooner CapitalALALTITUDE LIFE SCIENCE VENTURESFOFoley Ventures

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

GLGregory L. Verdine(Executive Officer, Director)GVGregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsARARCH Venture PartnersGVGV (Google Ventures)RARA CapitalAIAisling CapitalALAlexandriaBEBezos Expeditions+7 more

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

AWAetna Wun Trombley(President and CEO)inABAmy Bachrodt(Chief Financial Officer)inCLChin Lee(Chief Medical Officer)inSSSteve Staben(Chief Scientific Officer)inSTSofia Touami(Chief Business Officer)inKFKaren Flick(General Counsel)in

Co-investorsREREDMILEVEVersant VenturesBABAM ElevateFRFranklin TempletonHBHBM Healthcare InvestmentsJAJanus Henderson Investors+4 more

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Co-investorsAGage1ECEcoR1 CapitalLALAVLILifeSci Venture PartnersLILilly Asia VenturesNENew Enterprise Associates (NEA)+8 more

Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.

Cloud ComputingEnterprise SoftwareFintechSaaS

Co-investorsNYNycaNYNyca PartnersARARCH Venture PartnersCOCore Venture CapitalFIFidelity InvestmentsOROrbiMed+3 more

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

MCMark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)

BoardPBPaul Berns(Director)

Co-investorsAQAquiline Technology GrowthARARCH Venture PartnersOROrbiMedSASanofi VenturesPOPoint72VEVenrock Healthcare Capital Partners

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAPAsit Parikh(Chief Executive Officer)in

Co-investorsLILifeSci Venture PartnersNENextech InvestTHThird Rock VenturesALAlexandriaCACasdin CapitalCRCreacion Ventures+3 more

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

GFGordon Freeman(Scientific Founder)XZXingXing Zang(Scientific Founder)inICIvan Cheung(Chief Executive Officer)inLGLeena Gandhi(Chief Medical Officer)inTNTatiana Novobrantseva(Chief Scientific Officer)inAHAxel Hoos(Director)

Co-investorsCACatalio Capital Management, LPMPMPM BioImpactSASanofi VenturesCACatalio Capital ManagementLELeaps by BayerSISixty Degree Capital

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

ILIlise Lombardo(Chief Executive Officer)inVKVolker Knappertz(Executive Vice President of Research & Development)inMSMichael Samar(Chief Financial Officer)inRLRob Lasser(Chief Medical Officer)in

Co-investorsBIBioMedPartnersJEJeito CapitalRORoche Venture FundSOSofinnova PartnersEQEQTEQEQT Life Sciences+2 more

OneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development.

AI & Machine LearningBiotechDigital HealthMedical DevicesParis, FR

CVCéline Vallot(Co-founder & CSO)in

Co-investorsGAGalion.exePOPolytechnique VenturesKIKima VenturesREREDMILESOSofinnova Partners

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Co-investorsANAndreessen HorowitzARARCH Venture PartnersIGiGlobe PartnersAGAgent CapitalALAlexandriaCACasdin Capital+2 more

PayJoy provides financial services and credit access to unbanked and underbanked populations in emerging markets across Africa, Asia, and Latin America.

B2B MarketplacesFintechImpact & Social GoodRetail TechSan Francisco, US

MHMark Heynen(Co-Founder & Chief Business Officer)inDRDoug Ricket(Co-Founder & CEO)inGLGib Lopez(Co-Founder & COO)inTom Ricket(Co-Founder)inNZNick Zakrasek(President, Product Development)inAPAmy Pardee(General Counsel)in

Co-investorsCECeniarthCICiti VenturesCOCompoundCOCore Venture CapitalDNDnx VenturesECEchoVC Partners+18 more

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

MMMichal Minczuk(Co-Founder)inGMGabriel Martinez(Chief Scientific Officer & Co-Founder)CGClaes Gustafsson(Co-Founder)MFMaria Falkenberg(Co-Founder)NLNils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsARARCH Venture PartnersCACambridge Innovation CapitalEIEIR VenturesANAngelini VenturesGVGV (Google Ventures)HEHealthCap+1 more

Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.

Co-investorsSOSofinnova PartnersREREDMILESASanofi Ventures

Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.

BiotechHealthtechLongevityWaltham, US

Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)

Co-investorsARARCH Venture PartnersF-F-Prime CapitalYUYuanBio Venture CapitalCBCBC GroupEIEight Roads VenturesFUFuture Innovation+5 more

BiotechWatertown, US

Robert S. Langer, Sc.D.(Director)ASArmon Sharei, Ph.D.(Executive Officer, Director)ASArmon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)

Co-investors+N+ND CapitalGVGV (Google Ventures)ILIllumina VenturesJDJDRF T1D FundQUQuark Venture Inc.TETemasek+1 more

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

Co-investorsAIAisling CapitalARARCH Venture PartnersQUQuan CapitalALAlexandriaALAlly Bridge GroupBABain Capital+6 more

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

VPVishal Patelin

Co-investorsASAscenta CapitalATAtlas VentureBOBorealis VenturesBOBorealis VenturesMAMagnetic VenturesOROrbiMed+3 more

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsAGage1ARARCH Venture PartnersCYCycad Group LLCECEcoR1 CapitalKHKhosla VenturesVEVenrock+5 more

Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development.

BiotechHealthtech

DLDave Lennon, PhD(President & CEO)DLDave Lennon(President & CEO)in

Co-investorsAVAvoro Capital Advisors